Tonix Pharmaceuticals increases ATM equity offering capacity from $150M to $400M

Tonix Pharmaceuticals Holding Corp.

Sales Agreement with A.G.P./Alliance Global Partners amended to raise maximum aggregate offering price to $400M from $150M.
Amendment dated November 21, 2025; shares to be sold through at-the-market (ATM) issuance.
Company filed legal opinion from Brownstein Hyatt Farber Schreck on share legality.
Fundraising capacity more than doubled; no stated use of proceeds in the filing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Tonix Pharmaceuticals Holding Corp. amended Sales Agreement with A.G.P./Alliance Global Partners (effective 2025-11-21).

Action: amendment
Agreement: atm program
Counterparty: A.G.P./Alliance Global Partners
Effective: 2025-11-21

Exact text from the filing

On November 21, 2025, Tonix Pharmaceuticals Holding Corp. (the “Company”) amended its Sales Agreement with A.G.P./Alliance Global Partners, dated as of June 11, 2025 (as amended, the “Sales Agreement”), to allow for an increase to the maximum aggregate offering price of shares issuable under the Sales Agreement (the “Amendment”).

View on SEC.gov

273 material agreements filed in the last 30 days. Browse all material agreements →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001999371-25-018392

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.